CN118909082A - 一种分离的肽 - Google Patents

一种分离的肽 Download PDF

Info

Publication number
CN118909082A
CN118909082A CN202410999144.6A CN202410999144A CN118909082A CN 118909082 A CN118909082 A CN 118909082A CN 202410999144 A CN202410999144 A CN 202410999144A CN 118909082 A CN118909082 A CN 118909082A
Authority
CN
China
Prior art keywords
seq
peptide
tumor
cells
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410999144.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·T·P·库玛雅
T·贝卡伊-萨布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Mayo Clinic in Florida
Original Assignee
Ohio State Innovation Foundation
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation, Mayo Clinic in Florida filed Critical Ohio State Innovation Foundation
Publication of CN118909082A publication Critical patent/CN118909082A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN202410999144.6A 2017-03-28 2018-03-28 一种分离的肽 Pending CN118909082A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762477895P 2017-03-28 2017-03-28
US62/477,895 2017-03-28
CN201880022159.XA CN110636855B (zh) 2017-03-28 2018-03-28 人pd1肽疫苗及其用途
PCT/US2018/024831 WO2018183488A1 (en) 2017-03-28 2018-03-28 Human pd1 peptide vaccines and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880022159.XA Division CN110636855B (zh) 2017-03-28 2018-03-28 人pd1肽疫苗及其用途

Publications (1)

Publication Number Publication Date
CN118909082A true CN118909082A (zh) 2024-11-08

Family

ID=63678120

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410999144.6A Pending CN118909082A (zh) 2017-03-28 2018-03-28 一种分离的肽
CN201880022159.XA Active CN110636855B (zh) 2017-03-28 2018-03-28 人pd1肽疫苗及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880022159.XA Active CN110636855B (zh) 2017-03-28 2018-03-28 人pd1肽疫苗及其用途

Country Status (11)

Country Link
US (1) US11684660B2 (enExample)
EP (1) EP3600398B1 (enExample)
JP (1) JP7346302B2 (enExample)
KR (1) KR102653567B1 (enExample)
CN (2) CN118909082A (enExample)
AU (2) AU2018243920B2 (enExample)
BR (1) BR112019020386A2 (enExample)
CA (1) CA3058393A1 (enExample)
ES (1) ES2963635T3 (enExample)
RU (1) RU2019131252A (enExample)
WO (1) WO2018183488A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019153042A1 (en) * 2018-02-07 2019-08-15 Imugene Limited A vaccine composition and uses thereof
JP7304421B2 (ja) * 2018-10-05 2023-07-06 アールエヌエージーン インコーポレイテッド 標的細胞特異的に結合して多重免疫機能が強化されたキメラ抗原及びこの用途
BR112022005044A2 (pt) * 2019-09-17 2022-07-05 Ohio State Innovation Foundation Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
US20260007730A1 (en) * 2022-04-21 2026-01-08 Ohio State Innovation Foundation Human ctla-4 peptide vaccines and uses thereof
WO2024211745A1 (en) * 2023-04-05 2024-10-10 Ohio State Innovation Foundation Human pd1, pd-l1, and ctla-4 combination peptide vaccines and uses thereof
CN119019569B (zh) * 2024-08-19 2025-10-24 中国人民解放军陆军军医大学 一种可定向增强胸腺新生t细胞杀伤乳腺癌的多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) 1968-10-17 1970-08-24
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
WO1997038011A1 (en) * 1996-04-03 1997-10-16 Pepresearch A/S Non-dendritic backbone peptide carrier
FR2765243B1 (fr) 1997-06-30 1999-07-30 Usinor Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction
EP1651258B1 (en) * 2003-07-30 2014-03-19 Vaccine Research Institute of San Diego Hepatitis virus core proteins as vaccine platforms and methods of use thereof
GB0400440D0 (en) * 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
AU2006261342B2 (en) * 2005-06-15 2012-02-02 The Ohio State University Research Foundation Her-2 peptides
HUE032379T2 (en) * 2007-07-27 2017-09-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
AU2009274568A1 (en) * 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Proteins for use in diagnosing and treating infection and disease
US20100234283A1 (en) * 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
NZ713461A (en) * 2011-04-15 2017-02-24 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
IN2014KN00920A (enExample) * 2012-06-21 2015-10-09 Compugen Ltd
US9381244B2 (en) * 2012-09-07 2016-07-05 King's College London VISTA modulators for diagnosis and treatment of cancer
WO2014161509A1 (en) 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
CN105377897A (zh) * 2013-05-03 2016-03-02 俄亥俄州创新基金会 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
US9969986B2 (en) 2014-08-08 2018-05-15 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
PT3177640T (pt) * 2014-08-08 2020-08-31 Univ Leland Stanford Junior Agentes pd-1 de alta afinidade e métodos de utilização
DK3237446T3 (en) * 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer

Also Published As

Publication number Publication date
AU2018243920A1 (en) 2019-10-31
US11684660B2 (en) 2023-06-27
CA3058393A1 (en) 2018-10-04
KR20190137826A (ko) 2019-12-11
US20200197498A1 (en) 2020-06-25
RU2019131252A (ru) 2021-04-28
AU2025201760A1 (en) 2025-05-22
ES2963635T3 (es) 2024-04-01
JP2020512375A (ja) 2020-04-23
RU2019131252A3 (enExample) 2021-06-01
CN110636855B (zh) 2024-08-09
EP3600398A1 (en) 2020-02-05
KR102653567B1 (ko) 2024-04-02
EP3600398B1 (en) 2023-09-13
BR112019020386A2 (pt) 2020-06-09
JP7346302B2 (ja) 2023-09-19
WO2018183488A1 (en) 2018-10-04
CN110636855A (zh) 2019-12-31
AU2018243920B2 (en) 2024-12-12
EP3600398A4 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
CN110636855B (zh) 人pd1肽疫苗及其用途
TWI777996B (zh) 靶向ｃｄ１２７之抗體和多肽
CN114630676B (zh) 人抗pd-l1肽疫苗及其使用方法
JP7324565B2 (ja) Ｃｄ１２７に対する抗体
CZ297633B6 (cs) Pouzití BCMA pro výrobu farmaceutického prípravkupro lécení nádoru exprimujících APRIL
TR201816597T4 (tr) Gfr 3'e karşı insan antikorları ve bunların kullanım metotları.
CN112079922B (zh) 抗人p40蛋白域抗体及其用途
HK40119599A (zh) 一种分离的肽
US20260007730A1 (en) Human ctla-4 peptide vaccines and uses thereof
HK40013362A (en) Human pd1 peptide vaccines and uses thereof
WO2024211745A1 (en) Human pd1, pd-l1, and ctla-4 combination peptide vaccines and uses thereof
HK40067806A (en) Human anti-pd-l1 peptide vaccines and methods of their use
JP2022527541A (ja) 抗ｈｌａ－ｃ抗体及びその使用
WO2020033925A2 (en) Antibodies that bind cd277 and uses thereof
HK40012892A (en) Antibodies and polypeptides directed against cd127
HK40012892B (en) Antibodies and polypeptides directed against cd127
HK1259426A1 (zh) Pd-l1抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40119599

Country of ref document: HK